{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:53:58Z","timestamp":1781920438931,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejps.2023.106405","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T17:25:43Z","timestamp":1676049943000},"page":"106405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: A semiphysiologically based population pharmacokinetic modeling approach"],"prefix":"10.1016","volume":"184","author":[{"given":"Zi-ran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-huan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-jie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-kang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2023.106405_bib0001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/psp4.12346","article-title":"Semimechanistic population pharmacokinetic model to predict the drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers","volume":"7","author":"Ashraf","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106405_bib0002","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/bdd.732","article-title":"Determination of a quantitative relationship between hepatic CYP3A5*1\/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations","volume":"31","author":"Barter","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/psp4.12048","article-title":"Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients","volume":"5","author":"Brill","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106405_bib0004","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.ejps.2023.106405_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2023.106405_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105448","article-title":"Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients","volume":"152","author":"Cai","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2023.106405_bib0007","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/ajt.15602","article-title":"Prospective study of the changes in pharmacokinetics of immunosuppressive medications after laparoscopic sleeve gastrectomy","volume":"20","author":"Chan","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejps.2023.106405_bib0008","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11095-022-03289-9","article-title":"Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax","volume":"39","author":"Dong","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2023.106405_bib0009","unstructured":"FDA, Accessed 2022 Nov. Tacrolimus (PROGRAF) Package Insert. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/050708s054,050709s047,204096s010lbl.pdf."},{"key":"10.1016\/j.ejps.2023.106405_bib0010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40262-013-0070-9","article-title":"A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole","volume":"52","author":"Frechen","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.ejps.2023.106405_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12660","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"20","author":"Gavald\u00e0","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejps.2023.106405_bib0012","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1208\/s12248-014-9577-8","article-title":"Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach","volume":"16","author":"G\u00e9rard","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2023.106405_bib0013","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0014","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1124\/dmd.111.039248","article-title":"Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction","volume":"39","author":"Gertz","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/11538690-000000000-00000","article-title":"Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients","volume":"50","author":"Han","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105199","article-title":"Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model","volume":"143","author":"Huang","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2023.106405_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2018.01.004","article-title":"Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using LCMS\/MS","volume":"53","author":"Jenkins","year":"2018","journal-title":"Clinical Biochem."},{"key":"10.1016\/j.ejps.2023.106405_bib0018","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","article-title":"Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A","volume":"53","author":"Jeong","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2023.106405_bib0019","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2147\/TCRM.S184376","article-title":"CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation","volume":"14","author":"Ji","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejps.2023.106405_bib0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106405_bib0021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106405_bib0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejps.2023.106405_bib0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-019-00856-z","article-title":"A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and predictions of drug-drug interactions","volume":"59","author":"Li","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445896","article-title":"Limited sampling strategy for the estimation of tacrolimus area under the concentration-time curve in chinese adult liver transplant patients","volume":"98","author":"Liu","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejps.2023.106405_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1078155210397963","article-title":"A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients","volume":"18","author":"Lombardi","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejps.2023.106405_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40170-016-0162-8","article-title":"Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance","volume":"4","author":"Malvi","year":"2016","journal-title":"Cancer Metab."},{"key":"10.1016\/j.ejps.2023.106405_bib0027","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12185-012-1057-2","article-title":"Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation","volume":"95","author":"Mori","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejps.2023.106405_bib0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106405_bib0029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/bdd.1913","article-title":"Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506)","volume":"35","author":"Oda","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/bdd.1938","article-title":"In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure","volume":"36","author":"Oda","year":"2015","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-012-1300-z","article-title":"Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction","volume":"69","author":"Oteo","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106405_bib0032","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0033","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/11318130-000000000-00000","article-title":"Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil","volume":"49","author":"Perdaems","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0034","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11095-021-03019-7","article-title":"Modeling approach to predict the impact of inflammation on the pharmacokinetics of CYP2C19 and CYP3A4 substrates","volume":"38","author":"Simon","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2023.106405_bib0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0037","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1067\/mcp.2002.129304","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant recipients","volume":"72","author":"Staatz","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2023.106405_bib0038","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0039","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1111\/ajt.14232","article-title":"Determinants of the magnitude of interaction between tacrolimus and voriconazole\/posaconazole in solid organ recipients","volume":"17","author":"Vanhove","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejps.2023.106405_bib0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0041","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2023.106405_bib0042","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections","volume":"69","author":"Wang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2023.106405_bib0043","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/psp4.12052","article-title":"A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R","volume":"5","author":"Wang","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2023.106405_bib0044","article-title":"Simultaneous determination of tacrolimus and five main compounds of wuzhi capsule in liver transplant patients' whole blood by LC-MS\/MS","author":"Wang","year":"2016","journal-title":"Chin. J. Modern Appl. Pharmacy"},{"key":"10.1016\/j.ejps.2023.106405_bib0045","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1124\/dmd.110.032177","article-title":"Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0046","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1088\/0143-0815\/10\/3\/001","article-title":"Reference values for resting blood flow to organs of man","volume":"10","author":"Williams","year":"1989","journal-title":"Clin. Phys. Physiol. Meas."},{"key":"10.1016\/j.ejps.2023.106405_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacological Res."},{"key":"10.1016\/j.ejps.2023.106405_bib0048","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2023.106405_bib0049","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1124\/dmd.107.019646","article-title":"Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes","volume":"36","author":"Yanni","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2023.106405_bib0050","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","article-title":"A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children","volume":"53","author":"Zane","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2023.106405_bib0051","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","article-title":"Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients","volume":"45","author":"Zhu","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2023.106405_bib0052","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40262-020-00941-8","article-title":"Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling","volume":"60","author":"Zubiaur","year":"2021","journal-title":"Clin. Pharmacokinet."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:05:25Z","timestamp":1760529925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723000362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":52,"alternative-id":["S0928098723000362"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106405","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: A semiphysiologically based population pharmacokinetic modeling approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106405"}}